Novel Thrombopoietic Agents
Authors:
- Bethan PsailaBPBethan Psaila
Open Access
- 1 January 2007
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2007 (1) , 106-113
Abstract
Thrombocytopenia is a primary manifestation of immune thrombocytopenic purpura (ITP) and may occur as a result of hepatitis C, malignancy, and treatment with chemotherapy. There is a need for additional means to treat thrombocytopenia in these settings. Recombinant thrombopoietin-like agents became available after the cloning of thrombopoietin in 1994. In clinical trials, these agents showed some efficacy in chemotherapy-induced thrombocytopenia, but their use was ultimately discontinued due to the development of neutralizing antibodies that cross-reacted with endogenous thrombopoietin and caused thrombocytopenia in healthy blood donors and other recipients. Subsequently, “second-generation” thrombopoietic agents without homology to thrombopoietin were developed. In the past 5 years, these second-generation thrombopoeitic growth factors have undergone substantial clinical development and have demonstrated safety, tolerability and efficacy in subjects with ITP and hepatitis C–related thrombocytopenia. These completed studies, many of which are available only in abstract form, and other ongoing studies suggest that thrombopoietic agents will enhance the hematologist’s ability to manage these and other causes of thrombocytopenia.Keywords
This publication has 57 references indexed in Scilit:
- Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaAnnals of Oncology, 2007
- A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group ExperienceClinical Cancer Research, 2005
- Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over studyThe Lancet, 2002
- The role of transforming growth factor‐β in PEG‐rHuMGDF‐induced reversible myelofibrosis in ratsBritish Journal of Haematology, 1997
- Molecular cloning and chromosomal localization of the human thrombopoietin geneFEBS Letters, 1994
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesisNature, 1994
- Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivoNature, 1994
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994
- Treatment of Autoimmune Thrombocytopenic PurpuraNew England Journal of Medicine, 1989
- Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.Journal of Clinical Investigation, 1987